Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer

-- Dr. De La Rosa adds over 20 years of big pharma and biotech infectious disease clinical trial experience to Curevo Vaccine Seattle, WA – April 11, 2023 – Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced Dr. Guy De La Rosa has…

Curevo Vaccine Receives 2022 Best of Bothell Award

Bothell Award Program Honors the Achievement BOTHELL December 12, 2022 -- Curevo Vaccine has been selected for the 2022 Best of Bothell Award in the Corporate Office category by the Bothell Award Program. Each year, the Bothell Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and business category. These are local companies…

Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines

-- Curevo’s lead program is CRV-101, an adjuvanted subunit vaccine for shingles, which has completed enrollment in a 678-patient Phase 2b head-to-head trial of CRV-101 against Shingrix® with data due early 2023 November 16, 2022 10:00 AM Eastern Standard Time SEATTLE--(BUSINESS WIRE)--Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing…

Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101 Vaccine Against Shingles

-- Phase 2b trial enrolled 678 participants in six months -- Topline data from Phase 2b head-to-head trial of CRV‑101 against Shingrix® expected in early 2023 SEATTLE, Sept. 15, 2022 /PRNewswire/ -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced completion of enrollment in a Phase 2b trial of their CRV-101…

Vaccine startup Curevo takes on pharma giant GSK, raises $60M for trial of shingles shot

SEATTLE–(GEEKWIRE)–Curevo has raised $60 million to develop a new vaccine for shingles, an often-painful condition caused by reactivation of the chickenpox virus. The new funding will enable the Seattle-based startup to test its vaccine against a market-commanding shot made by GlaxoSmithKline. Curevo’s upcoming phase 2b trial will compare safety of the two vaccines in more than 650 people, and assess immune…

$60 Million Funding Supports Shingles Vaccine Candidate

(Precision Vaccinations) Washington-based Curevo Vaccine today announced the closing of a $60 million Series A financing round that would support the 678-patient Phase 2b head-to-head clinical trial of the CRV‑101 shingles vaccine candidate against Shingrix®, from initiation through topline data. CRV-101 is a clinical-stage adjuvanted sub-unit vaccine specifically designed to produce an optimal immune response while using a smaller amount of adjuvant with the intention of…

Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines

SEATTLE–(BUSINESS WIRE)–Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $60 million Series A financing round. “The upcoming Phase 2b trial is designed to compare CRV‑101’s immunogenicity and safety profile relative to Shingrix®. “I’m excited to close this financing and…

A small Seattle biotech wants to take on GlaxoSmithKline’s emerging Shingrix blockbuster. RA Capital is on board

GlaxoSmithKline’s Shingrix has quickly become one of the company’s best-selling products since first winning FDA approval in 2017. But a new biotech believes it can do better — and RA Capital is listening. Curevo Vaccine, a Seattle-based company, debuted a $60 million Series A on Thursday led by the prominent life sciences VC, aiming to fund a Phase IIb study…

Curevo Presenting at World Vaccine Conference Congress (Washington) Sept 28 – Oct 1

Curevo Vaccine’s Steve Reed, PhD, Scientific Advisory and Executive Board member, and Lisa Shelton, ARNP, Associated Director Clinical Operations,  will be presenting at World Vaccine Congress Wednesday, September 30 @ 4:50pm EST/1:50pm PST , on Low side-effect safety profile demonstrated in phase 1 trial of shingles vaccine candidate CRV-101.  Join us to hear about the safety and a sneak peek into the…

SAHPRA Approval Press Announcement 2021

CUREVO VACCINE ANNOUNCES THE APPROVAL TO CONDUCT A PHASE 1B CLINICAL TRIAL IN SOUTH AFRICA TO EVALUATE SAFETY AND IMMUNOGENICITY OF ITS ADJUVANTED SUBUNIT INVESTIGATIONAL VACCINE, CRV-101, AGAINST VARICELLA (CHICKENPOX) IN HIV-POSITIVE CHILDREN. Curevo Vaccine, a clinical-stage biopharmaceutical company combining excellence in protein and adjuvant biology to develop new generation sub-unit vaccines of global importance, announced today that approval was…